Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 25 vs ANDROGEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Primary hypogonadism (congenital or acquired),Hypogonadotropic hypogonadism,Off-label: delayed puberty in males, certain breast cancers
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
The terminal elimination half-life of testosterone from Andro Gel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Hepatic via CYP3A4, CYP2C9, and 17β-hydroxysteroid dehydrogenase; metabolites include estradiol and dihydrotestosterone.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
97–99% (sex hormone-binding globulin and albumin)
Approximately 98% of circulating testosterone is protein-bound: 40-50% bound to sex hormone-binding globulin (SHBG) and 50-60% loosely bound to albumin.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
The apparent volume of distribution of testosterone is about 1.0 L/kg, reflecting extensive distribution into tissues, particularly muscle, skin, and male reproductive organs.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
Bioavailability of testosterone from Andro Gel is approximately 10-14% of the applied dose, due to limited skin permeation and first-pass metabolism (though minimal with transdermal route). For comparison, oral testosterone bioavailability is <1%, while intramuscular testosterone enanthate has 100% bioavailability.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
No specific dose adjustment is provided for renal impairment. Use with caution in patients with severe renal impairment due to potential for fluid retention.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
Contraindicated in patients with Child-Pugh class C (severe hepatic impairment). Use with caution and monitor liver function in mild to moderate hepatic impairment; no specific dose reduction guidelines exist.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Not indicated in pediatric patients under 18 years of age; safety and efficacy have not been established.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
Elderly patients may be more sensitive to androgens, and require careful monitoring for prostate enlargement, prostate cancer, and fluid retention. Start at the lowest dose (25 mg daily) and titrate based on serum testosterone levels and clinical response.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
None.
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Risk of secondary exposure to testosterone (children) – avoid skin contact,Polycythemia (monitor hematocrit),Prostate enlargement/cancer risk,Cardiovascular risk (especially in elderly),Spermatogenesis suppression,Hepatic effects (monitor liver function),Edema (in patients with preexisting conditions)
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Known hypersensitivity to testosterone or gel components,Prostate cancer,Breast cancer (males),Women who are pregnant or may become pregnant (risk to fetus)
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
No specific food interactions. Grapefruit juice may increase testosterone levels due to CYP3A4 inhibition, but clinical significance is unclear. Avoid excessive alcohol intake as it may affect testosterone levels and liver function.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
Andro Gel (testosterone) is contraindicated in pregnancy. Testosterone is a teratogen with masculinization of female fetuses (clitoral enlargement, labial fusion, urogenital sinus abnormalities) when exposed during the first trimester. Second and third trimester exposure may cause pseudohermaphroditism in females. Risk is highest during the first 12 weeks of gestation.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
Testosterone is excreted into breast milk with an estimated M/P ratio of 0.1-0.3. It may cause virilization in nursing infants. Breastfeeding is not recommended during Andro Gel therapy.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
Andro Gel is contraindicated in pregnancy; no dose adjustments are applicable. If exposure occurs, discontinue immediately and monitor for fetal effects.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Apply to clean, dry, intact skin on shoulders, upper arms, or abdomen. Avoid application to genitals or chest due to higher absorption and risk of transfer. Wash hands after application. Allow gel to dry before dressing. Monitor serum testosterone, hematocrit, PSA, and lipid profile. Contraindicated in men with breast or prostate cancer. May cause erythrocytosis, sleep apnea, or worsening of BPH. Risk of testosterone transfer to women or children; cover application site or wash skin before contact.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
Apply Andro Gel once daily at the same time each morning to clean, dry, intact skin on shoulders, upper arms, or abdomen.,Do not apply to genitals or chest.,Wash hands thoroughly with soap and water after application.,Allow gel to dry completely before dressing or coming into contact with others.,Avoid swimming, showering, or bathing for at least 5 hours after application.,If skin contact with another person is likely, cover the application site with clothing or wash the area before contact.,Keep Andro Gel away from children and women of childbearing potential.,Report any signs of deep vein thrombosis (leg swelling, pain, warmth), heart attack (chest pain, shortness of breath), or stroke (sudden weakness, confusion, vision changes).,Regular blood tests are required to monitor testosterone levels, red blood cell count, prostate health, and cholesterol.,Andro Gel may interact with blood thinners (e.g., warfarin) and corticosteroids; inform all healthcare providers.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 25 vs ANDROGEL, answered by our medical review team.
ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. ANDROGEL is a Androgen that works by Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 25 and ANDROGEL depend on the specific clinical indication. These are both Androgen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. The standard adult dose of ANDROGEL is: 50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 25 and ANDROGEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. ANDROGEL is classified as Category C. AndroGel (testosterone) is contraindicated in pregnancy. Testosterone is a teratogen with masculinization of female fetuses (clitoral enlargement, labial fusion, urogenital sinus a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.